Page last updated: 2024-11-11

pseudopteroxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pseudopteroxazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6475529
CHEMBL ID469075
CHEBI ID66786
SCHEMBL ID13467076
MeSH IDM0397027

Synonyms (8)

Synonym
(1s,3ar,4s,6s)-1,4,7-trimethyl-6-(2-methylprop-1-enyl)-2,3,3a,4,5,6-hexahydro-1h-phenaleno[2,1-d]oxazole
pseudopteroxazole
(1s,3ar,4s,6r)-1,4,7-trimethyl-6-(2-methyl-propenyl)-2,3,3a,4,5,6-hexahydro-1h-10-oxa-8-aza-cyclopenta[a]phenalene
CHEMBL469075
chebi:66786 ,
(1s,3ar,4s,6s)-1,4,7-trimethyl-6-(2-methylprop-1-enyl)-2,3,3a,4,5,6-hexahydro-1h-phenaleno[2,1-d][1,3]oxazole
SCHEMBL13467076
Q27135417
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID623583Antimicrobial activity against Proteus vulgaris ATCC 12454 after 22 hrs by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID623582Antimicrobial activity against Pseudomonas aeruginosa ATCC 14210 after 22 hrs by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID623578Antimicrobial activity against Mycobacterium smegmatis ATCC 12051 after 5 days by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID1601824Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of mycobacterial growth at 12.5 ug/ml relative to control2019European journal of medicinal chemistry, Mar-01, Volume: 165Marine natural products as potential anti-tubercular agents.
AID356015Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2003Journal of natural products, Jun, Volume: 66, Issue:6
Homopseudopteroxazole, a new antimycobacterial diterpene alkaloid from Pseudopterogorgia elisabethae.
AID623580Antimicrobial activity against vancomycin-resistant Enterococcus faecium Ef 379 after 22 hrs by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID623579Antimicrobial activity against Mycobacterium diernhoferi ATCC 19340 after 5 days by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID623584Antimicrobial activity against Candida albicans ATCC 14035 after 22 hrs by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
AID358833Antitubercular activity against Mycobacterium tuberculosis H37Rv at 12.5 ug/ml2001Journal of natural products, Jan, Volume: 64, Issue:1
Serrulatane diterpenes with antimycobacterial activity isolated from the West Indian sea whip Pseudopterogorgia elisabethae.
AID623581Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 22 hrs by microbroth dilution antibiotic susceptibility assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (60.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]